U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H32O6
Molecular Weight 416.5082
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DESONIDE

SMILES

CC1(C)O[C@]2([H])C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@]([H])(C[C@]3(C)[C@]2(C(=O)CO)O1)O

InChI

InChIKey=WBGKWQHBNHJJPZ-LECWWXJVSA-N
InChI=1S/C24H32O6/c1-21(2)29-19-10-16-15-6-5-13-9-14(26)7-8-22(13,3)20(15)17(27)11-23(16,4)24(19,30-21)18(28)12-25/h7-9,15-17,19-20,25,27H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,20+,22-,23-,24+/m0/s1

HIDE SMILES / InChI
Desonide is a topical glucocorticoid which was approved by FDA for the treatment of such conditions as eczema, psoriasis, atopic dermatitis, etc. The exact mechanism of drug action is unknown.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DESONIDE

Approved Use

Desonide Ointment, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician.

Launch Date

6.3331201E10
Primary
DESONIDE

Approved Use

Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Launch Date

6.3331201E10
Primary
DESONIDE

Approved Use

Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Launch Date

6.3331201E10
Primary
DESONIDE

Approved Use

Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Launch Date

6.3331201E10
Primary
DESONIDE

Approved Use

Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Launch Date

6.3331201E10
Doses

Doses

DosePopulationAdverse events​
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.3
unhealthy
n = 425
Health Status: unhealthy
Condition: Atopic dermatitis
Population Size: 425
Sources: Page: p.3
Disc. AE: Telangiectasia...
AEs leading to
discontinuation/dose reduction:
Telangiectasia
Sources: Page: p.3
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Disc. AE: Cushing's syndrome, Hypothalamic pituitary adrenal axis suppression...
AEs leading to
discontinuation/dose reduction:
Cushing's syndrome
Hypothalamic pituitary adrenal axis suppression
Atrophy
Striae
Irritation skin
Acneiform eruption
Skin hypopigmentation
Allergic contact dermatitis
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Telangiectasia Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.3
unhealthy
n = 425
Health Status: unhealthy
Condition: Atopic dermatitis
Population Size: 425
Sources: Page: p.3
Acneiform eruption Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Allergic contact dermatitis Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Atrophy Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Cushing's syndrome Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Hypothalamic pituitary adrenal axis suppression Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Irritation skin Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Skin hypopigmentation Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Striae Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes (co-administration study)
Comment: Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide. If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered
Page: 4,8
PubMed

PubMed

TitleDatePubMed
Clinical comparison of alclometasone dipropionate and desonide ointments (0.05%) in the management of psoriasis.
1982
Allergic contact dermatitis from topical corticosteroids.
1989 Aug
A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis.
2002
Evaluation of cross-reactivity between budesonide and desonide.
2002 Aug
Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen) versus vehicle in the short-term treatment of facial atopic or seborrhoeic dermatitis.
2002 Aug
Efficacy and safety of desonide phosphate for the treatment of allergic conjunctivitis.
2002 Jul
Steroid therapy altered serum levels of CCL2 and CCL5 chemokines in multiple sclerosis patients during relapse.
2004
Overview on desonide 0.05%: a clinical safety profile.
2004 Jul-Aug
Two case reports of cutaneous adverse reactions following hepatitis B vaccine: lichen planus and granuloma annulare.
2004 Sep
Efficacy of desonide 0.05% cream and lotion in steroid-responsive dermatoses in Indian patients: a post-marketing surveillance study.
2004 Sep-Oct
[Connubial contact dermatitis to an inhaled corticosteroid].
2005 Feb
Comparison of the analysis of corticosteroids using different techniques.
2005 Jan
Seborrheic dermatitis.
2005 Jan-Feb
Erythematous scaling eyelids: patient history, exposure to allergens and irritants are keys to diagnosis.
2005 Jun
Corneofungimetry bioassay on Malassezia spp. under ketoconazole and desonide influences.
2005 Mar-Apr
Rapid resolution of a common problem.
2005 May
Photochemistry of desonide, a non-fluorinated steroidal anti-inflammatory drug.
2006 Jun
Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis.
2007 Feb
Verdeso (desonide) Foam, 0.05%.
2007 Jan-Feb
A novel hydrogel vehicle formulated for the treatment of atopic dermatitis.
2007 Jul
Ketoconazole gel 2% in the treatment of moderate to severe seborrheic dermatitis.
2007 Jun
Effect of desonide hydrogel 0.05% on the hypothalamic-pituitary-adrenal axis in pediatric subjects with moderate to severe atopic dermatitis.
2007 May-Jun
Periorbital cutaneous neonatal lupus.
2007 May-Jun
Tega-dermabrasion.
2007 Sep
Corticosteroid therapy in the treatment of pediatric patients with atopic dermatitis.
2007 Sep 20
Desonide gel.
2007 Sep-Oct
Desonide foam 0.05%: safety in children as young as 3 months.
2008 Aug
Nephrotic state as a risk factor for developing posterior reversible encephalopathy syndrome in paediatric patients with nephrotic syndrome.
2008 Aug
What's your assessment? Severe seborrheic dermatitis.
2008 Dec
New and emerging trends in the treatment of atopic dermatitis.
2008 Feb 2
Adverse cutaneous drug reaction.
2008 Jan
Desonide foam: a review.
2008 Jan
Desonide: a review of formulations, efficacy and safety.
2008 Jul
Worrisome perioral rash on a young boy. Lip-licker's dermatitis.
2008 May
Direct injection LC/ESI-MS horse urine analysis for the quantification and identification of threshold substances for doping control. I. Determination of hydrocortisone.
2008 Sep
A simple and rapid ESI-LC-MS/MS method for simultaneous screening of doping agents in urine samples.
2009 Apr
Fixed drug eruption induced by atenolol.
2009 Apr 24
Rhabdomyomatous mesenchymal hamartoma: clinical overview and report of a case with spontaneous regression.
2009 Dec
Treatment of scalp and facial seborrheic dermatitis with desonide hydrogel 0.05%.
2009 Feb
[Streptococcal perianal dermatitis and guttate psoriasis].
2009 Jan
Inflammation of actinic keratosis with combination of alkylating and taxane agents: a case report.
2009 Jul 2
Manifestations of cutaneous sarcoidosis: a case report of an African American woman.
2009 Jun
An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face.
2009 Nov-Dec
Drugs associated with more suicidal ideations are also associated with more suicide attempts.
2009 Oct 2
Vitiligo after diphencyprone for alopecia areata.
2010
Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents.
2010
Good adherence and early efficacy using desonide hydrogel for atopic dermatitis: results from a program addressing patient compliance.
2010 Apr
Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories.
2010 Apr
Update on the management of chronic eczema: new approaches and emerging treatment options.
2010 Jul 28
Pediatric atopic dermatitis: a review of the medical management.
2010 Sep
Patents

Sample Use Guides

Desonide Cream, 0.05% should be applied to the affected area as a thin film two to four times daily depending on the severity of the condition.
Route of Administration: Topical
In Vitro Use Guide
Unknown
Name Type Language
DESONIDE
INN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
DESONIDE [MART.]
Common Name English
DESONIDE COMPONENT OF TRIDESILON
Common Name English
DESONIDE [ORANGE BOOK]
Common Name English
TRIDESILON COMPONENT DESONIDE
Common Name English
DESONIDE [USAN]
Common Name English
DESONIDE [USP MONOGRAPH]
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 11,21-DIHYDROXY-16,17-((1-METHYLETHYLIDENE)BIS(OXY))-, (11.BETA.,16.ALPHA.)-
Common Name English
VERDESO
Brand Name English
11.BETA.,16.ALPHA.,17,21-TETRAHYDROXYPREGNA-1,4-DIENE-3,20-DIONE CYCLIC 16,17-ACETAL WITH ACETONE
Common Name English
DESOWEN
Brand Name English
DESONIDE [USP-RS]
Common Name English
D-2083
Code English
DESONIDE [VANDF]
Common Name English
D2083
Code English
DESONIDE [INN]
Common Name English
NSC-759226
Code English
DESONIDE [MI]
Common Name English
DESONIDE [WHO-DD]
Common Name English
DESONATE
Brand Name English
Classification Tree Code System Code
WHO-ATC S01BA11
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
NDF-RT N0000175450
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
WHO-VATC QS01BA11
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
WHO-ATC D07BB02
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
WHO-VATC QD07BB02
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
WHO-ATC D07AB08
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
WHO-VATC QD07AB08
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
NDF-RT N0000175576
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
NCI_THESAURUS C521
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
Code System Code Type Description
EPA CompTox
638-94-8
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
PRIMARY
CAS
638-94-8
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
PRIMARY
ChEMBL
CHEMBL1201109
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
PRIMARY
IUPHAR
7066
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
PRIMARY
WIKIPEDIA
DESONIDE
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
PRIMARY
DRUG CENTRAL
3135
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
PRIMARY
INN
2889
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
PRIMARY
DRUG BANK
DB01260
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
PRIMARY
ECHA (EC/EINECS)
211-351-6
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
PRIMARY
LACTMED
Desonide
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
PRIMARY
PUBCHEM
5311066
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
PRIMARY
MESH
D003898
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
PRIMARY
EVMPD
SUB07005MIG
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
PRIMARY
USP_CATALOG
1173304
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
PRIMARY USP-RS
RXCUI
3254
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
PRIMARY RxNorm
FDA UNII
J280872D1O
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
PRIMARY
NCI_THESAURUS
C61702
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
PRIMARY
MERCK INDEX
M4199
Created by admin on Fri Jun 25 21:59:41 UTC 2021 , Edited by admin on Fri Jun 25 21:59:41 UTC 2021
PRIMARY Merck Index